AlgoDx is driven by a team of dedicated leaders who are passionate about leveraging machine learning to deliver evidence-based solutions that improve healthcare outcomes.
Inger Persson, PhD, Assoc Prof, dept of Statistics at Uppsala University
Director AI & Biostatistics
Bringing together more than ten years of clinical trials expertise in the medtech and pharmaceutical sectors, coupled with another decade of university biostatistics research, Inger offers profound theoretical and practical knowledge in medical data science to our team. In her role at AlgoDx, she spearheads AI and biostatistics initiatives, encompassing multivariate analysis, prediction modeling, and time-to-event analysis. Additionally, she leads machine learning research and development efforts while overseeing the expansion of AlgoDx’s scientific publications portfolio.
David Becedas, M Sc Pharm
CEO
Bringing over two decades of expertise in clinical research, David is a seasoned leader adept at navigating complex projects with precision, consistently delivering results that drive commercial success. With prior experience spanning pharmaceuticals, medtech, and CRO sectors, he offers a unique blend of strategic vision and hands-on execution tailored to drive business growth at AlgoDx.
Calle Österlind, Physics and Computer Science Engineer
CIO
Drawing upon twenty-five years of software development expertise, complemented by a decade of leadership experience, Calle epitomizes a seasoned senior tech professional. His career has been characterized by a consistent focus on driving digital transformation, with the last five years dedicated primarily to building and scaling tech departments. Calle’s background in medtech, showcased through his previous role as CTO at Doktor.se, underpins his responsibility for spearheading the development of the AlgoDx Platform and guiding our tech team.
Andreas Macura, M Sc Pharm
CPO & QA
Andreas, a seasoned healthcare professional with over a decade of experience in pharmaceutical and clinical research, serves as Chief Product Officer and Head of Quality Assurance at AlgoDx. In this role,he oversees product development, quality management, and marketing/sales efforts in Europe. His expertise ensures that AlgoDx delivers innovative, high-quality products that meet market needs.
AlgoDx Board of Directors
The AlgoDx Board includes, in addition to the founder David Becedas the following board members.
Dr. Enrico Petrillo, MD
Chairman of the board
Dr. Petrillo is a seasoned professional with a multifaceted career, excelling as a venture capitalist, academic physician, and national policy advisor. Currently, he serves as an influential figure at Brigham and Women’s Hospital, leading international research programs for Harvard Medical School. As a co-founder of two successful venture capital firms, he boasts a remarkable track record with significant returns. His impact extends to strategic roles in technology commercialization and advising on groundbreaking medical therapies. Dr. Petrillo is a respected leader whose expertise spans medicine, business, and academia, shaping the landscape of research and innovation.
Claudia Hidou, M Sc Strategy, MIB
Board member
Ms. Hidou brings a wealth of experience in management consulting and facilitating the expansion of Nordic companies into North America. Presently, she holds dual roles as the Head of New York and Head of Life Science and Healthcare for the Americas at Business Sweden.
Joseph Slote, M Sc Math
Board member
Previously serving as the Director of Science and Technology at Dascena, Inc., Joseph has transitioned to pursuing a graduate degree in Theoretical Computer Science at the California Institute of Technology. Concurrently, he acts as a technical and scientific advisor to AlgoDx, focusing on bridging the theory-to-practice gap in ML-driven healthcare.
Erik Gozzi, M Sc Finance
Board member
Erik serves as a managing partner at Nascent Invest, boasting a proven track record in early-stage company investments. With extensive experience garnered from numerous high-growth ventures, he has played pivotal roles in several successful exits. Before joining Nascent Invest, Erik spent a decade as an auditor at Deloitte in Stockholm.